Elevance Health, Inc. (ELV) is an Indiana-based managed healthcare provider with a market cap of $71.3 billion, offering a range of services including medical, behavioral health, and dental care through brands like Anthem Blue Cross and Blue Shield.

ELV stock has declined 41.7% over the past year and 14.2% YTD, falling behind the S&P 500 Index and Health Care Select Sector SPDR Fund.

Elevance Health released its second-quarter earnings, with revenue growing by 14% year over year to $49.4 billion. However, rising ACA and Medicaid costs led to a drop in adjusted EPS and net income, with the company’s medical loss ratio worsening to 88.9%.

Analysts expect ELV’s EPS to decline by 9.6% year over year to $29.88 for the current year ending in December. The stock has a consensus rating of “Moderate Buy” among analysts.

Wells Fargo analyst Stephen Baxter reiterated an “Overweight” rating on Elevance Health but lowered the price target from $400 to $330. ELV’s mean price target of $366.33 indicates a 15.7% premium from current prices.

Read more at Yahoo Finance: What Are Wall Street Analysts’ Target Price for Elevance Health Stock?